MedPath

Whole Body Electromyostimulation and Nutritional Therapy for Patients With Esophageal and Bronchial Carcinoma

Not Applicable
Conditions
Cancer of Esophagus
Cancer, Lung
Interventions
Procedure: whole body electromyostimulation exercise
Procedure: protein-rich nutrition therapy
Registration Number
NCT03274349
Lead Sponsor
University of Erlangen-Nürnberg Medical School
Brief Summary

The objective or the trial is to study the influence of a combined therapy involving protein-rich individualized nutritional therapy and highly effective muscle training via personalized whole-body electromyostimulation exercise on muscle mass, muscle functionality, physical capability, fatigue and quality of life in patients with esophageal and bronchial carcinoma in advanced or metastatic stage.

Detailed Description

Tumor specific and inflammation promoting mediators lead to a loss of appetite, to systemic inflammation processes and to metabolic and hormonal changes including anabolic resistance. Consequences hereof are a decreased food uptake, a deteriorated nutrient utilization and a loss of muscles and/or fat leading to cancer cachexia. In addition, an accelerated muscle wasting can be a side effect of the oncologic therapy promoting cancer cachexia even further. The advancing muscle loss induces diminishing physical capability, a decreased tolerance of oncological therapy, functional losses even reaching loss of independence and a worsened prognosis.

The purpose of this study is to establish an innovative combined therapy involving protein-rich nutritional therapy and highly effective muscle training by personalized whole-body electromyostimulation (WB-EMS) exercise to improve muscle mass, functionality and strength of esophageal and bronchial carcinoma patients in advanced stage. An increase in muscle mass and strength leads to an increase in physical activity, physical capability as well as tolerance to and applicability of tumor therapy. In the course of a 3-months intervention study the efficacy of a combined protein-rich nutritional therapy with an innovative exercise therapy will be documented for patients with esophageal and bronchial carcinoma in advanced or metastatic stage. An effective stopping of the progress of muscle wasting or even increase of muscle mass, strength and function in the patients of the trial would benefit each patient and his family individually, since it could mean a considerable improvement in his quality of life and tolerability of oncological treatment.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
150
Inclusion Criteria
  • Patients with esophageal and/or bronchial carcinoma in curative or palliative treatment
Exclusion Criteria
  • Healthy persons or patients under age
  • Pregnancy, Lactation
  • Psychological disorders, epilepsia, sever neurological disorders
  • Participation in other exercise- or nutrition studies within the last 6 months
  • Acute cardiovascular disease
  • Rheuma
  • Intake of anabolic drugs,
  • Skin injuries in the area of electrode placements
  • Electronic implants (defibrillator, pacemaker)
  • Persons in mental hospitals by order of authorities or jurisdiction

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
EMS-groupwhole body electromyostimulation exerciseGroup of patients receiving individualized protein-rich nutritional therapy with personalized whole body electromyostimulation exercise, 12 weeks intervention per patient
Controlprotein-rich nutrition therapyGroup of patients receiving individualized protein-rich nutritional therapy without exercise, 12 weeks intervention per patient
EMS-groupprotein-rich nutrition therapyGroup of patients receiving individualized protein-rich nutritional therapy with personalized whole body electromyostimulation exercise, 12 weeks intervention per patient
Primary Outcome Measures
NameTimeMethod
Muscle mass maintenance or increase, as assessed by Bioelectrical Impedance Analysis12 weeks per patient

Maintenance or increase of skeletal muscle mass in patients with esophagus or bronchial carcinoma receiving a combined therapy of protein-rich nutrition and WB-EMS, by assessing Bioelectrical Impedance Analysis values.

Secondary Outcome Measures
NameTimeMethod
Improvement of pain scores, as assessed by Visual Analog Score12 weeks per patient

Clinical improvement by an increase of pain scores in patients with esophagus or bronchial carcinoma receiving a combined therapy of protein-rich nutrition and WB-EMS.

Maintenance or increase in Body Mass Index (BMI) in kg/m^2-analysis (combination of weight in kilograms and height and in meters12 weeks per patient

Maintenance or increase of skeletal muscle mass in patients with esophagus or bronchial carcinoma receiving a combined therapy of protein-rich nutrition and WB-EMS, by assessing BMI in kg/m\^2 (combination of weight in kilograms and height in meters).

Increase in quality of life score by assessing the score points using EORTC-QLQ-C30 questionnaires12 weeks per patient

Clinical improvement by an increase in quality of life in patients with esophagus or bronchial carcinoma receiving a combined therapy of protein-rich nutrition and WB-EMS.

Increase or maintenance of muscle strength, as assessed by hand grip strength measurements (Jamar dynamometry)12 weeks per patient

Clinical improvement by an increase in muscle strength in patients with esophagus or bronchial carcinoma receiving a combined therapy of protein-rich nutrition and WB-EMS.

Improvement of oncological therapy tolerance, as assessed by Common Toxicity Criteria regarding gastrointestinal complaints12 weeks per patient

Clinical improvement oncology therapy tolerance in patients with esophagus or bronchial carcinoma receiving a combined therapy of protein-rich nutrition and WB-EMS.

Improvement of fatigue scores, as assessed by FACIT-Fatigue Score12 weeks per patient

Clinical improvement by an increase of fatigue scores in patients with esophagus or bronchial carcinoma receiving a combined therapy of protein-rich nutrition and WB-EMS.

Trial Locations

Locations (1)

University Hospital Erlangen, Department of Medicine 1

🇩🇪

Erlangen, Bavaria, Germany

© Copyright 2025. All Rights Reserved by MedPath